PTC Therapeutics, Inc. - Common Stock - fluxo de caixa trimestral (NASDAQ:PTCT)

Financials

Fluxo de caixa operacional -30 M870.1 M-58.33 M-66.3 M-34.27 M-59.04 M -217.95 M Fluxo de caixa de investimento 267.71 M-184.36 M-422.01 M-289.62 M34.01 M-93.74 M -771.36 M Fluxo de caixa de financiamento 26.47 M9.41 M3.96 M15.22 M302.5 M6.4 M 328.09 M Fluxo de caixa livre -30 M870.1 M-62.33 M-322.5 M-71.56 M-60.4 M -516.78 M

PTC Therapeutics, Inc. - Common Stock

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.

PTCT

Financials

PTC Therapeutics, Inc. - Common Stock

Notícias

Jefferies eleva recomendação da PTC Therapeutics com base nas perspectivas do Sephience

Leqembi Isn’t Enough To Save Biogen Momentum (NASDAQ:BIIB)

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

BofA reitera recomendação de compra para PTC Therapeutics citando momentum do lançamento do Sephience

PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage

TD Cowen eleva recomendação da PTC Therapeutics com lançamento do Sephience

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics